Defunct Company
Total Trials
7
As Lead Sponsor
As Collaborator
0
Total Enrollment
419
NCT04795141
ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis
Phase: Phase 2
Role: Lead Sponsor
Start: Aug 24, 2021
Completion: Aug 30, 2022
NCT05353972
Evaluate IMG-007 in Healthy Participants
Phase: Phase 1
Start: Jul 5, 2022
Completion: May 31, 2023
NCT05349097
Study to Evaluate IMG-004 in Healthy Participants
Start: Aug 8, 2022
Completion: May 2, 2024
NCT05984784
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)
Phase: Phase 1/2
Start: Aug 9, 2023
Completion: Apr 26, 2024
NCT06060977
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants
Start: Sep 25, 2023
Completion: Jan 14, 2025
NCT06304740
Safety and Pharmacokinetics of Subcutaneous Dose of IMG-007 in Healthy Participants
Start: Mar 6, 2024
Completion: Aug 28, 2024
NCT07037901
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Start: Jun 17, 2025
Completion: Oct 31, 2027